The Latest Breaking News from Novartis AG

As a slowdown in monetary policy tightening is paving its way, the possibility of a soft landing still stands. Therefore, it could be an ideal opportunity for investors to load up on some fundamentally sound growth stocks, Novartis (NVS), Daimler Truck Holding (DTRUY), and CPI Aerostructures (CVU). Read on….

With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy is likely to enter a recession, making pharma stocks attractive investment options. Therefore, investors could look to…

Amid soaring concerns over an impending Fed-induced recession, the stock market could remain volatile in the near future. Against this backdrop, investors could add stable stocks Johnson & Johnson (JNJ) and Novartis (NVS) to their portfolios in 2023 to garner good returns. Read on….

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

The stock market witnessed a solid start this year amid improving investors’ optimism. Moreover, experts see increased chances of a soft landing. So, fundamentally strong stocks Merck (MRK), Novartis (NVS), Sysco (SYY), Progress Software (PRGS), and LSI Industries (LYTS) could be solid buys now. These stocks pay consistent dividends. Read…

Although headline inflation has slowed, the Fed will likely keep raising interest rates to attain its 2% target. However, a potential slowdown in monetary policy tightening is opening the path for quality stocks to recover. Therefore, investors should consider buying fundamentally sound stocks Merck & Co. (MRK), Novartis (NVS), and…

The Fed’s intention to continue raising interest rates, disappointing economic data, and a weak earnings season could keep the stock market highly volatile. Hence, investing in quality stocks Microsoft (MSFT), Johnson (JNJ), and Novartis (NVS) could be safe. Continue reading.

The pharma industry is well-placed to benefit from the rise of chronic diseases and an aging population. Moreover, given the stable demand for medicines, the industry is relatively unaffected by macroeconomic uncertainty. Therefore, it could be wise for investors to buy fundamentally strong pharma stocks AstraZeneca (AZN) and Novartis (NVS).…

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core therapeutic areas, having multiple significant in-market and pipeline assets. Given NVS’ reliable dividend payments and high profitability, this large-cap stock…